Hoerger, T.J.* et al. A new type 2 diabetes microsimulation model to estimate long-term health outcomes, costs, and cost-effectiveness. Value Health 26, 1372-1380 (2023)
Seidl, H. et al. Cost-effectiveness of a specialized breathlessness service versus usual care for patients with advanced diseases. Value Health 26, 81-90 (2023)
Böckmann, D. et al. Cost-effectiveness of pulmonary rehabilitation in patients with bronchial asthma: An analysis of the EPRA randomized controlled trial. Value Health 24, 1254-1262 (2021)
Laxy, M. et al. Utility decrements associated with diabetes and related complications: Estimates from a population-based study in Germany. Value Health 24, 274-280 (2021)
Shao, H.* ; Laxy, M. ; Gregg, E.W.* ; Albright, A.* & Zhang, P.* Cost-effectiveness of the new 2018 American college of physicians glycemic control guidance statements among US adults with type 2 diabetes. Value Health 24, 227-235 (2021)
Maqhuzu, P.N. et al. Predictors of health-related quality of life decline in intersitial lung disease using the K-bild questionnaire. Value Health 23, S360-S360 (2020)
Kirsch, F. et al. Influence of COPD severity and its comorbidities on direct and indirect costs: Results from the LQ-DMP study. Value Health 22, S876-S876 (2019)
Maqhuzu, P.N. ; Kreuter, M.* & Schwarzkopf, L. Cost of healthcare resource utilization in interstitial lung diseases in Germany in 2017. Value Health 22, S845-S845 (2019)
Szentes, B.L. et al. The suitablility of the EQ-5D-5L in asthma patients. Value Health 22, S882-S882 (2019)
Arnold, M. & Quante, A.S. Personalized mammography screening and screening adherence-A simulation and economic evaluation. Value Health 21, 799-808 (2018)
Szentes, B.L. ; Kirsch, F. ; Schramm, A.* ; Schwarzkopf, L. & Leidl, R. Association between severe, moderate and mild exacerbations with generic health-related quality of life in COPD patients. Value Health 21, S419-S419 (2018)
Walter, J. & Schwarzkopf, L. First insights into comparing expenditures for targeted therapy and survival in NSCLC. Value Health 21, S35-S35 (2018)
Arnold, M.* & Quante, A.S. Risk-stratified breast cancer screening and non-adherence in Germany. Value Health 20, A442-A442 (2017)
Hoogendoorn, M.* et al. External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): Report of the third COPD modeling meeting. Value Health 20, 397-403 (2017)
Kirsch, F.* ; Becker, C. ; Maier, W. & Schramm, A.* Effects of adherence to pharmacological secondary prevention after myocardial infarction on healthcare expenditures. Value Health 20, A609-A609 (2017)
Laxy, M. ; Wilson, E.C.F.* ; Boothby, C.E.* & Griffin, S.J.* Incremental costs and cost-effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK trial: An update with empirical trial-based cost data. Value Health 20, 1288-1298 (2017)
Leidl, R. & Reitmeir, P. An experience-based value set for the EQ-5D-5L in Germany. Value Health 20, 1150-1156 (2017)
Seidl, H. et al. The 3-year cost-effectiveness of a nurse-based case management versus usual care for elderly patients with myocardial infarction: Results from the KORINNA follow-up study. Value Health 20, 441-450 (2017)
Szentes, B.L. et al. Quality of life assessment in ILD - a comparison of  EQ-5D with the disease-specific K-bild. Value Health 20, A649-A649 (2017)
Walter, J. ; Tufman, A.* ; Holle, R. & Schwarzkopf, L. Comparison of costs and care of lung cancer patient at the end-of-life in Germany depending on the tome of survival after diagnosis. Value Health 20, A511-A511 (2017)
Arnold, M.* & Quante, A.S. Personalized mammography screening and screening adherence - a simulation of cost-effectiveness. Value Health 19, A738-A738 (2016)
Danner, M.* et al. Economic modeling of risk-adapted screen-and-treat strategies in women at high-risk for breast or ovarian cancer. Value Health 19, A737-A738 (2016)
Hoogendoorn, M.* et al. Patient heterogeneity in health economic decision models for Chronic Obstructive Pulmonary Disease: Are current models suitable to evaluate personalized medicine?. Value Health 19, 800-810 (2016)
Kirsch, F. Economic evaluations of multicomponent disease management programs with Markov models: A systematic review. Value Health 19, 1039-1054 (2016)
Leidl, R. & Reitmeir, P. Analyzing a German index for the EQ-5D-5L based on experienced health. Value Health 19, A386-A386 (2016)
Szentes, B.L. et al. Current practice of drug treatment in children with ILD: First insights from the child-EU registry. Value Health 19, A558-A558 (2016)
Walter, J. et al. Manual compression versus vascular closing device for closing access puncture site in femoral left-heart catheterization and percutaneous coronary interventions: A retrospective cross-sectional comparison of costs and effects in inpatient care. Value Health 20, 769-776 (2016)
Hoogendoorn, M.* et al. Patient heterogeneity in cost-effectiveness models for Chronic Obstructive Pulmonary Disease (COPD): Are current models suitable to evaluate personalized medicine. Value Health 18:A694 (2015)
Laxy, M. et al. The burden of diabetes mellitus in patients with coronary heart disease: A methodological approach to assess quality-adjusted life-years based on individual-level longitudinal survey data. Value Health 18, 969-976 (2015)
Brandes, A. et al. Cost-effectiveness of radical prostatectomy, radiation therapy and active surveillance for the treatment of localized prostate cancer - a claims data analysis. Value Health 17, A636-A637 (2014)
Butzke, B. et al. Cost-effectiveness analysis of ugt1a1 genotyping before colorectal cancer treatment with irinotecan. Value Health 17, A643 (2014)
Hoogendoorn, M.* et al. Cost-effectiveness models for chronic obstructive pulmonary disease: Cross-model comparison of hypothetical treatment scenarios. Value Health 17, 525-536 (2014)
Hoogendoorn, M.* et al. Cost-effectiveness models for Chronic Obstructive Pulmonary Disease (COPD): Cross-model comparison of hypothetical treatment scenarios. Value Health 17, A557-A558 (2014)
Laxy, M. et al. The intermediate burden of diabetes mellitus in patients with cardiovascular disease (CVD): A quality adjusted life year (QALY) - analysis based on primary longitudinal data. Value Health 17, A494 (2014)
Little, M.H.R. ; Reitmeir, P. ; Peters, A. & Leidl, R. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups. Value Health 17, 364-371 (2014)
Rochau, U.* et al. Prioritization of future outcomes research studies in chronic myeloid leukemia: Value of information analysis. Value Health 17, A639 (2014)
Leidl, R. ; Reitmeir, P. ; König, H.-H.* & Stark, R.G. The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease. Value Health 15, 151-157 (2012)
Menn, P. et al. Dementia care in the general practice setting: A cluster randomized trial on the effectiveness and cost impact of three management strategies. Value Health 15, 851-859 (2012)
Rottenkolber, D. ; Hasford, J.* & Stausberg, J.* Costs of adverse drug events in German hospitals - a microcosting study. Value Health 15, 868-875 (2012)
Hunger, M. ; Baumert, J.J. & Holle, R. Analysis of SF-6D index data: Is beta regression appropriate? Value Health 14, 759-767 (2011)
Schwarzkopf, L. et al. Costs of care for dementia patients in community setting: An analysis for mild and moderate disease stage. Value Health 14, 827-835 (2011)
Schweikert, B.* et al. Standards for the assessment of antidiabetic drugs-the IQWIG perspectice. Value Health 13, A300-A300 (2010)
Happich, M. ; Moock, J.* & von Lengerke, T. Health state valuation methods and reference points: The case of tinnitus. Value Health 12, 88-95 (2009)
Graf von der Schulenburg, J.M.* et al. German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. Value Health 11, 539-544 (2008)